Study guide
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion
Key Takeaways Explain This Topic AI
A total anterior circulation stroke requires all three of higher cortical dysfunction, homonymous hemianopia and motor/sensory deficit affecting at least two of face, arm and leg.
Lateral medullary (Wallenberg) syndrome from posterior inferior cerebellar artery occlusion causes ipsilateral facial sensory loss, Horner syndrome and ataxia with contralateral body sensory loss.
Alteplase is given within 4.5 hours of onset after haemorrhage is excluded; mechanical thrombectomy is offered for proximal anterior circulation occlusion, with selected patients treated well beyond 6 hours on perfusion imaging.
Last updated: September 2026
Cerebrovascular disease represents one of the most heavily tested topics in MRCP(UK) Part 1. Candidates must master clinical anatomical localization via the Oxford Community Stroke Project (Bamford) classification, hyperacute reperfusion protocols (intravenous thrombolysis and mechanical thrombectomy), physiological blood pressure targets, secondary prevention algorithms, urgent transient ischaemic attack (TIA) pathways, and the emergency management of intracranial haemorrhage.
1. Oxford Community Stroke Project (Bamford) Classification
The Bamford (OCSP) classification is a validated clinical bedside tool used to classify acute ischaemic stroke based entirely on presenting signs and symptoms prior to neuroimaging. It predicts underlying vascular anatomy, infarct volume, risk of early recurrence, and 1-year mortality.
Classification Clinical Criteria & Defining Features Vascular Territory & Anatomy 1-Year Mortality & Recurrence Risk
Total Anterior Circulation Stroke (TACS) Complete triad of:; 1. Hemiparesis and/or hemisensory loss (contralateral face, arm, and leg); 2. Homonymous hemianopia (contralateral); 3. Higher cortical dysfunction (dysphasia/aphasia, or visuospatial neglect/inattention) Proximal Middle Cerebral Artery (MCA stem) or Internal Carotid Artery (ICA) terminus occlusion; extensive frontotemporoparietal hemispheric infarction Highest mortality (~60% at 1 year) ; low recurrence rate (~6%) because of high early case fatality; high risk of malignant cerebral oedema
Partial Anterior Circulation Stroke (PACS) 2 of the 3 TACS triad components , OR isolated higher cortical dysfunction alone (e.g. pure expressive dysphasia), OR restricted motor/sensory deficit (e.g. monoparesis of one limb or face + arm only) Branch/distal MCA occlusion (anterior or posterior division), or Anterior Cerebral Artery (ACA) cortical branches Intermediate mortality (~15% at 1 year); highest early recurrence risk (~17% at 1 year) due to unstable emboligenic arterial or cardiac sources
Lacunar Stroke (LACS) Subcortical stroke presenting with one of four classical lacunar syndromes :; 1. Pure motor hemiparesis; 2. Pure sensory stroke; 3. Sensorimotor stroke; 4. Ataxic hemiparesis (or clumsy-hand dysarthria); Crucially: NO visual field defect, NO higher cortical dysfunction, NO brainstem signs Lipohyalinosis and microatheroma of small, deep penetrating end-arteries: lenticulostriate (off MCA), thalamoperforating (off PCA), or paramedian pontine branches. Involves posterior limb of internal capsule, thalamus, or base of pons Lowest early mortality (~10% at 1 year) ; intermediate recurrence risk (~10%); best functional recovery if rehabilitation is instituted early
Posterior Circulation Stroke (POCS) Any of the following focal signs:; 1. Cerebellar dysfunction (ataxia, nystagmus, dysdiadochokinesia); 2. Brainstem syndromes / crossed cranial nerve palsies with contralateral long tract motor/sensory deficits; 3. Isolated homonymous hemianopia or cortical blindness; 4. Bilateral motor or sensory deficits; 5. Conjugate gaze palsy or disordered ocular motility Vertebrobasilar arterial system: Vertebral arteries, Basilar artery, Posterior Cerebral Arteries (PCA), or cerebellar arteries (PICA, AICA, SCA) Variable mortality (~20–30% at 1 year); high risk of basilar artery thrombosis (which carries >80% mortality if recanalisation is delayed)
MRCP Exam Pearl: Defining Higher Cortical Dysfunction: In Bamford criteria, higher cortical dysfunction strictly denotes dysphasia/aphasia, visuospatial neglect, apraxia, agnosia, or conjugate gaze deviation away from the hemiparetic side. Dysarthria alone is a motor articulatory symptom and does not count as higher cortical dysfunction; isolated dysarthria with hemiparesis constitutes a lacunar syndrome (LACS).
2. Vascular Brainstem Syndromes
Crossed neurological findings—ipsilateral cranial nerve palsy combined with contralateral body motor or sensory hemiparesis—are the hallmark of brainstem stroke. MRCP Part 1 frequently assesses lateral medullary and paramedian midbrain syndromes:
Feature / Finding Wallenberg Syndrome (Lateral Medullary Syndrome) Weber Syndrome (Paramedian Midbrain Syndrome)
Culprit Arterial Vessel Posterior Inferior Cerebellar Artery (PICA) (in ~20%) or culprit parent Vertebral Artery occlusion (in ~80%) Paramedian perforating branches of the Posterior Cerebral Artery (PCA) or top of the basilar artery
Anatomical Structures Involved 1. Nucleus ambiguus (CN IX, X); 2. Spinal trigeminal nucleus & tract (CN V); 3. Descending sympathetic tract; 4. Inferior cerebellar peduncle; 5. Spinothalamic tract 1. Oculomotor nerve (CN III) fascicles; 2. Crus cerebri (cerebral peduncle / descending corticospinal & corticobulbar tracts)
Ipsilateral Clinical Signs - Dysphagia, hoarseness, impaired gag reflex, palatal paralysis (nucleus ambiguus); - Facial pain and temperature sensation loss (spinal trigeminal nucleus); - Horner's syndrome (miosis, partial ptosis, anhidrosis from descending sympathetics); - Cerebellar ataxia, dysmetria, past-pointing (inferior cerebellar peduncle) - Complete CN III palsy : Ptosis, widely dilated and unreactive pupil, eye positioned "down and out" due to unopposed action of lateral rectus (CN VI) and superior oblique (CN IV)
Contralateral Clinical Signs - Loss of pain and temperature sensation over trunk and limbs (lateral spinothalamic tract) - Contralateral spastic hemiparesis/hemiplegia of the face, arm, and leg (interruption of corticospinal and corticobulbar fibres in crus cerebri)
Sparing / Negative Features - Corticospinal tract is spared (runs in the medial medulla / anterior pyramid); therefore, there is NO limb motor hemiplegia in Wallenberg syndrome - Sensation and cerebellar coordination are typically preserved
- 3. Acute Ischaemic Stroke: Hyperacute Reperfusion Pathways
- Immediate Emergency Neuroimaging
Every patient with suspected acute stroke requires an immediate unenhanced non-contrast CT head to differentiate ischaemic stroke from intracerebral haemorrhage. CT excludes haemorrhage and identifies early ischaemic changes (loss of grey-white matter differentiation, insular ribbon sign, sulcal effacement, hyperdense MCA sign).
Intravenous Thrombolysis (IV Alteplase)
Indication & Window: Recombinant tissue plasminogen activator (rt-PA, alteplase 0.9 mg/kg , maximum 90 mg; administered as a 10% IV bolus over 1 minute followed by 90% infused over 60 minutes). Recommended for patients presenting within 4.5 hours of known symptom onset (or time last known well) where intracerebral haemorrhage is excluded.
Absolute Contraindications to Thrombolysis (High-Yield MRCP List):
Intracranial haemorrhage on current CT, or any past medical history of intracerebral haemorrhage.
Known intracranial arteriovenous malformation (AVM), aneurysm, or intracranial neoplasm.
Active internal bleeding, gastrointestinal haemorrhage within previous 21 days, or severe trauma/major surgery within previous 14 days.
Ischaemic stroke or severe head injury within previous 3 months.
Coagulopathy: Platelet count < 100 × 10 9 / L < 100 \times 10^9/\text{L} < 100 × 1 0 9 / L , INR > 1.7 > 1.7 > 1.7 , prothrombin time > 15 seconds > 15\text{ seconds} > 15 seconds , or activated partial thromboplastin time (aPTT) elevated.
Direct Oral Anticoagulant (DOAC) ingestion within previous 48 hours (unless specific reversal agent administered or sensitive drug level assays prove negligible anticoagulant activity).
Persistent severe hypertension: Systolic BP > 185 mmHg > 185\text{ mmHg} > 185 mmHg or Diastolic BP > 110 mmHg > 110\text{ mmHg} > 110 mmHg refractory to rapid intravenous antihypertensive therapy.
Lumbar puncture or arterial puncture at a non-compressible site within previous 7 days.
Mechanical Thrombectomy (Endovascular Clot Retrieval)
Standard Indication (0–6 Hours): Recommended within 6 hours of symptom onset for confirmed anterior circulation Large Vessel Occlusion (LVO: intracranial internal carotid artery or proximal middle cerebral artery M1 segment) in patients with independent baseline functional status (modified Rankin Scale mRS 0–2).
Extended Window (6–24 Hours): Indicated up to 24 hours from last known well (including wake-up strokes) in selected patients demonstrating clinical-core or perfusion mismatch on advanced CT perfusion or diffusion-weighted MRI (DAWN and DEFUSE 3 trial criteria: small ischaemic core with substantial salvageable penumbra).
Blood Pressure Management in Acute Ischaemic Stroke
Permissive Hypertension Principle: Cerebral autoregulation is disrupted in acute ischaemia; perfusion to the ischaemic penumbra depends passively on mean arterial pressure. Precipitous blood pressure reduction induces penumbral infarction and worsens clinical outcome.
Guideline-Directed Thresholds (NICE / ESO):
Non-thrombolysed patients: Do NOT treat blood pressure unless severe hypertension is present: Systolic BP > 220 mmHg > 220\text{ mmHg} > 220 mmHg or Diastolic BP > 120 mmHg > 120\text{ mmHg} > 120 mmHg , or there is concurrent hypertensive target organ damage (e.g. acute aortic dissection, acute pulmonary oedema, hypertensive encephalopathy). If > 220 / 120 mmHg > 220/120\text{ mmHg} > 220/120 mmHg , lower BP cautiously by no more than 15 % 15\% 15% over the initial 24 hours.
Thrombolysed / Thrombectomy candidates: Blood pressure must be lowered to < 185 / 110 mmHg < 185/110\text{ mmHg} < 185/110 mmHg before initiating alteplase and maintained < 180 / 105 mmHg < 180/105\text{ mmHg} < 180/105 mmHg for at least 24 hours post-reperfusion to prevent fatal reperfusion haemorrhagic transformation. First-line IV agents: intravenous labetalol, nicardipine, or hydralazine.